Literature DB >> 18501763

Pharmacokinetics and pharmacodynamics in the critically ill child.

Athena F Zuppa1, Jeffrey S Barrett.   

Abstract

An understanding of pharmacokinetics and pharmacodynamics can allow for a rational approach to prescribing medications for critically ill children. Absorption, distribution, metabolism, elimination, and the response to medications are affected by age and disease state. Various medications are used in the care of critically ill children. Many medications are prescribed for children based on dosing guidance from adult studies, however. Care providers must be cautious of the high risk for drug interactions and adverse reactions in the intensive care setting.

Entities:  

Mesh:

Year:  2008        PMID: 18501763     DOI: 10.1016/j.pcl.2008.02.017

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  10 in total

1.  Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study.

Authors:  Athena F Zuppa; Daniela J Conrado; Nicole R Zane; Martha A Q Curley; Jonathan Bradfield; Hakon Hakonarson; Madeleine S Gastonguay; Ganesh Moorthy; Janice Prodell; Marc R Gastonguay
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

Review 2.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

Review 3.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

4.  Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

Authors:  A Kontou; K Sarafidis; O Begou; H G Gika; A Tsiligiannis; K Ogungbenro; A Dokoumetzidis; E Agakidou; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.

Authors:  Wei Zhao; Daolun Zhang; Thomas Storme; André Baruchel; Xavier Declèves; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2015-09-05       Impact factor: 4.335

Review 6.  Optimal sedation in pediatric intensive care patients: a systematic review.

Authors:  Nienke J Vet; Erwin Ista; Saskia N de Wildt; Monique van Dijk; Dick Tibboel; Matthijs de Hoog
Journal:  Intensive Care Med       Date:  2013-06-19       Impact factor: 17.440

7.  Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design.

Authors:  Karin Kipper; Charlotte I S Barker; Joseph F Standing; Mike Sharland; Atholl Johnston
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Relationship between dexmedetomidine dose and plasma dexmedetomidine concentration in critically ill infants: a prospective observational cohort study.

Authors:  Yoshihito Fujita; Koichi Inoue; Tasuku Sakamoto; Saya Yoshizawa; Maiko Tomita; Toshimasa Toyo'oka; Kazuya Sobue
Journal:  Korean J Anesthesiol       Date:  2017-02-21

Review 9.  Pharmacokinetic studies in children: recommendations for practice and research.

Authors:  Charlotte I S Barker; Joseph F Standing; Lauren E Kelly; Lauren Hanly Faught; Allison C Needham; Michael J Rieder; Saskia N de Wildt; Martin Offringa
Journal:  Arch Dis Child       Date:  2018-04-19       Impact factor: 3.791

10.  Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.

Authors:  Janneke M Brussee; Nienke J Vet; Elke H J Krekels; Abraham J Valkenburg; Evelyne Jacqz-Aigrain; Joop M A van Gerven; Eleonora L Swart; Johannes N van den Anker; Dick Tibboel; Matthijs de Hoog; Saskia N de Wildt; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2017-11-29       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.